• Janssen Biotech Inc., of Horsham, Pa., a unit of Johnson & Johnson, reported data from the 52-week TRANSIT study at the European Academy of Dermatology and Venereology congress in Prague, Czech Republic, demonstrating that Stelara (ustekinumab) is effective, generally well tolerated and improves quality of life in patients with moderate to severe plaque psoriasis. Read More
• Sanofi SA, of Paris, and Bristol-Myers Squibb Co. (BMS), of New York, restructured their long-term alliance following the loss of exclusivity of Plavix (clopidogrel bisulfate) and Avapro (irbesartan)/Avalide (irbesartan-hydrochlorothiazide) in most markets. Read More
• Depomed Inc., of Menlo Park, Calif., presented additional data from its Phase III trial, BREEZE 3, suggesting Serada, its nonhormonal extended-release formulation of gabapentin, may help manage menopausal hot flashes. Read More
• Epizyme Inc., of Cambridge, Mass., disclosed $4 million in milestone payments from collaborator GlaxoSmithKline plc, of London, based on achieving preclinical goals. Read More
• Abbott, of Abbott Park, Ill., was sentenced by District Court Judge Samuel G. Wilson of the Western District of Virginia in connection with the firm's guilty plea related to unlawful off-label promotion of anticonvulsant drug Depakote (valproic acid), the Justice Department announced Wednesday. Read More
Sialix Inc. raised its biotech cred by inking an option agreement to license an undisclosed monoclonal antibody (mAb) therapeutic program with Momenta Pharmaceuticals Inc. Read More
A public offering worth $130 million will extend Rigel Pharmaceuticals Inc.'s cash runway through potential approval of its lead product, fostamatinib. Read More
According to the March of Dimes charity, 10 percent to 15 percent of all newborns are admitted to the neonatal intensive care unit (NICU). Many of those babies suffer from genetic disorders. In fact, Stephen Kingsmore told reporters at a press conference, at his hospital – Children's Mercy Hospital in Kansas City – "the leading cause to admission to a neonatal intensive care unit is an illness that is likely to be genetic." Read More
